[go: up one dir, main page]

EP0199535B2 - Lactobacillus acidophilus strains of bacteria and compositions thereof - Google Patents

Lactobacillus acidophilus strains of bacteria and compositions thereof Download PDF

Info

Publication number
EP0199535B2
EP0199535B2 EP86302836A EP86302836A EP0199535B2 EP 0199535 B2 EP0199535 B2 EP 0199535B2 EP 86302836 A EP86302836 A EP 86302836A EP 86302836 A EP86302836 A EP 86302836A EP 0199535 B2 EP0199535 B2 EP 0199535B2
Authority
EP
European Patent Office
Prior art keywords
bacteria
strain
nutrient medium
cells
bile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP86302836A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0199535B1 (en
EP0199535A3 (en
EP0199535A2 (en
Inventor
Sherwood L. Gorbach
Barry R. Goldin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GORBACH-GOLDIN Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24909071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0199535(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to AT86302836T priority Critical patent/ATE71140T1/de
Publication of EP0199535A2 publication Critical patent/EP0199535A2/en
Publication of EP0199535A3 publication Critical patent/EP0199535A3/en
Publication of EP0199535B1 publication Critical patent/EP0199535B1/en
Application granted granted Critical
Publication of EP0199535B2 publication Critical patent/EP0199535B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/854—Lactobacillus acidophilus

Definitions

  • This invention relates to therapeutically beneficial strains of bacteria, and particularly to strains of Lactobacillus acidophilus .
  • L . acidophilus is a component of the normal intestinal flora of most healthy human beings.
  • the genus Lactobacillus is widely distributed in nature. Many species, such as L . bulgaricus and L . casei , are found in dairy products, as well as in fruits and vegetables. Other Lactobacillus species are encountered in the intestinal tract of mammals and insects. For many centuries, lactobacilli have been used in milk and dairy products as fermentation organisms, producing yogurt and various types of fermented and soured milks, curds and creams.
  • the species of Lactobacillus used in the dairy industry is generally L. bulgaricus , although L . acidophilus strains have been used fairly extensively as well.
  • NCSU North Carolina State University
  • the present invention features a new strain which exhibit a number of characteristics which render them beneficial to human health, and in particular render them useful in the treatment of the side effects of antibiotic therapy, ulcerative colitis, and constipation; in providing resistance to gastrointestinal colonization by pathogenic microorganisms and yeasts; in reducing fecal cholesterol excretion; and in reducing fecal estrogen excretion.
  • the strains of the invention are characterized in that an average of at least 50, more preferably at least 100, of the bacteria can adhere to one human small intestinal mucosal cell after a five minute incubation of the bacteria with the cells.
  • the bacteria are further characterized in that they produce at least 3.5 milliequivalents ("meq") of lactic acid per 1010 CFU (colony forming units) in nutrient medium at 37°C per day; they are capable of proliferating at 37°C in nutrient medium at a pH value of 3.0; they are capable of proliferating in nutrient medium containing 0.1% oxgall bile; and they exhibit a generation time of less than one hour in nutrient medium at 37°C.
  • Nutrient medium refers to any culture medium containing the nutrients required for the proliferation of L. acidophilus bacteria.
  • the invention also provides a method for isolating strains of the invention from a sample containing a multiplicity of bacterial strains, involving carrying out, in any order, the screening steps of isolating bacteria of the species L. acidophilus , and associating the bacteria with gastrointestinal cells and selecting bacteria capable of adhering to the cells at a rate of an average of at least 50, and more preferably at least 100, bacterial cells per gastrointestinal cell in a five-minute coincubation period.
  • the selection method also includes the steps of incubating bacteria of the sample in nutrient medium at a pH value of 3.0 and selecting bacteria which proliferate in that medium; incubating bacteria in nutrient medium at 37°C and selecting bacteria that produce at least 3.5 milliequivalents of lactic acid per 1010 CFU per day; incubating bacteria of the sample in nutrient medium containing at least 0.1% bile and selecting bacteria which proliferate in that medium; and incubating bacteria of the sample with nutrient medium and selecting bacteria having a generation time of less than one hour at about 37°C.
  • Healthy human beings carry bacteria of the species L. acidophilus as part of their normal flora, generally in concentrations of about 10 lactobacilli per gram of intestinal contents; thus a healthy individual harbors in excess of 10 lactobacilli in his intestinal tract.
  • the first step in the method is to screen faecal specimens from humans and select those in which high lactobacillus concentrations are present.
  • LBS agar (described in J. Bacteriol. (1951) 62 , 132) is prepared, having the following composition, per liter: Triptycose and Peptone 10.0g Yeast Extract 5.0g Ammonium Citrate 2.0g Monopotassium Phosphate 6.0g Dextrose 20.0g Polysorbate PO4 1.0g Sodium Acetate Hydrate 25.0g Magnesium Sulfate 0.575g Manganese Sulfate 0.12g Ferrous Sulfate 0.034g Agar 15.0g
  • MRS broth Screening for stability to more acidic conditions is carried out using MRS broth (Difco; described in J. Applied Bacteriol. (1960) 23 , 130), of the composition: Bacto-Protease Peptone #3 10.0g Bacto-Beef Extract 10.0g Bacto-Yeast Extract 5.0g Dextrose 20.0g Tween 80 1.0g Ammonium citrate 2.0g Sodium acetate 5.0g Magnesium sulfate 0.1g Manganese sulfate 0.05g Disodium phosphate 2.0g
  • 55g of powder of the above composition, dehydrated, is mixed with 1000 ml distilled water and sterilized by autoclaving for 15 min. at 15 lb.
  • the broth has a final pH value of 6.5 at 25°C.
  • the pH is then adjusted using 1.0 M HCl and, if necessary, 1.0 N NaOH, and the broth filter sterilized.
  • Bacteria are incubated in the broth for 48 hours in an anaerobic chamber. Selected bacteria preferably can proliferate at pH below 3.5, preferably at pH 3.0.
  • the next screening step is the isolation, from the bacteria able to proliferate in acid and bile, of bacteria of the species L. acidophilus . This step is carried out using standard microbiological techniques. Adherence
  • the next step is to test acid and bile-stable bacteria for the ability to adhere to gastrointestinal cells.
  • Human gastrointestinal cells are first isolated, by any convenient method. One technique involves the collection of the effluent from a patient with a well-functioning ileostomy by saline lavage.
  • the saline effluent is collected in cold 1/10 volume buffer I (0.1% gelatin, 1% glucose, 500 mM sodium phosphate, pH 7.4). This solution is then filtered through #25 silk to remove clumps and debris and the small intestinal (ileal) mucosal cells collected by centrifugation at 100 x g for 10 min. The cells are then washed in buffer II (0.45% NaCl, 0.1% glucose, 0.01% gelatin, 50 mM sodium phosphate, pH 7.4) using the same centrifuge conditions. Finally, the cells are resuspended in buffer II, 1/3 volume of tissue culture medium NCTC 135 is added, and the cells are stored at 4°C until use. Ileal cell number and viability are determined by Trypan Blue staining. The human ileal cells can be frozen in liquid nitrogen after the addition of 10% (v/v) glycerol.
  • the bacteria are grown for 18 hours at 37°C in MRS broth with 6 uCi of 3H-alanine and 3H-leucine added. The bacteria are then washed in 5 volumes of phosphate buffered saline, resuspended in buffer II, and filtered through 2.0 u polycarbonate filters to remove clumps. The bacteria are then mixed with the human small intestinal cells, incubated at 37°C, and samples taken 5 minutes later. The samples are placed on 2.0 u polycarbonate filters and the excess liquid removed by gentle suction. The filters are then rinsed, first with 2 ml then with 5 ml of phosphate buffered saline (pH 7.4).
  • Controls include the reaction mixture without the human small intestinal cells.
  • the radioactivity retained is determined by liquid scintillation.
  • the bacterial specific activity is determined from the colony forming units calculated from the optical density at 550 nm and the radioactivity retained by 0.2 u filters. The bacterial specific activity is used to calculate the numbers of bacteria bound.
  • Bacteria which bind, according to the above procedure, at a rate of at least 50, and more preferably 100, bacteria per gastrointestinal cell (representing approximately 10% of the bacteria contacted with the cells) are the desired bacteria.
  • Lactic acid production is measured by incubating bacteria in MRS broth or Scott Peptone Yeast Broth under anaerobic conditions and measuring lactic acid at 8 or 24 hours using gas-liquid chromatography. Selected bacteria produce at least 3.5 meq, and more preferably over 4 meq, of lactic acid per 1010 CFU at 37°C in a 24-hour period.
  • the final screening step is the selection of bacteria which exhibit hardy growth in vitro , as measured by generation time.
  • 5 x 104 CFU of bacteria are used to inoculate nutrient medium, e.g., MRS broth, and CFU measured at 1, 2, 3, 4, 5, 6, 7, and 8 hours by plating 0.1 ml of diluted aliquots onto LBS agar and incubating plates for 48 hours at 37°C under anaerobic conditions.
  • Bacteria are selected which have a generation time, at 37°C, of less than one hour, more preferably about 45 minutes.
  • Each step in the above screening procedure is designed to isolate strains possessing characteristics which render them capable of enhancing human health.
  • Acid and bile stability are important because the bacteria are ingested and must pass through the acidic environment of the stomach as well as the bile-containing small intestine, and they must be able to survive and proliferate under these conditions if the bacteria are to confer health benefits on the person ingesting them.
  • Adherence is important because this property permits the bacteria to colonize and become established in the gastrointestinal tract.
  • Lactic acid production is important because it is believed that the lactic acid produced by the bacteria is in part responsible for the beneficial effects of colonization of the gastrointestinal tract by the strains of the invention. Lactic acid is an antimicrobial substance, and its production by the strains of the invention can help them form a protective barrier to pathogens within the gastrointestinal tract. Lactic acid may also aid in the inactivation of carcinogens in the gastrointestinal tract.
  • Hardy in vitro growth is an important property because the strains of the invention must be produced on a large scale; hardy growth is also an indicator that the bacteria will likely grow well in vivo as well.
  • GG One strain of the invention, designated GG, has the following characterics.
  • the GG strain can grow at pH 3.0 up to a concentration of 1 X 107 CFU. At higher pH's the growth is even higher, achieving 109 CFU at pH 5.0.
  • the GG strain In normal human gastric juice, the GG strain, starting at an inoculum of 108 CFU, can survive, with less than 2 log decline in inoculum size, for at least 30 minutes at pH 2.5.
  • Bacteria of the GG strain (109 CFU) were inoculated down a Levine tube directly into the stomach of a healthy volunteer. With gastric contents at pH 1.0-2.0, at least 1.000 organisms of the GG strain survived for a minimum of two hours.
  • the GG strain could grow in oxgall bile at a concentration of 0.15% in LBS agar.
  • the GG strain exhibited hardy growth in vitro .
  • the strain Using an initial inoculum of 5 X 104 CFU in MRS broth, the strain showed a 40-fold increase in growth during a four-hour period, reaching a density of 2 X 106 CFU. Thus, during this four-hour period there were 5.2 generations, giving a single generation time of 45 minutes.
  • the strains of the invention can be cultured on a large scale and used therapeutically, in lyophilized form or in conjunction with a pharmaceutically acceptable carrier substance, and can be added to food products, particularly dairy products such as milk and yogurt, as has been done with L . acidophilus strains for many years.
  • the bacteria of the strains, alone, in food, or in other carrier vehicles, can be taken orally by a human patient, in an effective amount (e.g., 106-1010 bacteria per person per day) to treat or prevent a variety of medical disorders, mentioned above and now discussed in more detail.
  • Culture conditions are as follows.
  • a stock solution consists of sterile skim milk containing 1010 CFU viable organisms. 1 ml of this stock solution is added to 2 liters of MRS broth. The vessel is placed in an anaerobic incubation chamber and grown overnight for 14 hours with general stirring at 37°C. The broth is centrifuged at 10,000 x g for 20 minutes, and the pellet is resuspended in 50-100 ml of sterile skim milk and stored at -80°C.
  • 109 to 1010 organisms are added to milk, either in volumes of 10 to 20 ml, or larger volumes, e.g., 250 to 500 ml.
  • the milk is administered once daily, so that 109 to 1010 CFU are given in a single administration.
  • 0.2 to 1.0 ml of the stock milk solution is mixed into their food, so that they receive 109 to 1010 CFU of the bacteria daily.
  • Diarrhea is the major complication of antibiotic treatment, occurring in approximately 10% of patients receiving antibiotics, particularly ampicillin, amoxacillin, cephalosporins, clindamycin, erythromycin, and tetracyclines.
  • the strains of the invention can be used to treat antibiotic-induced diarrhea, in the same manner that L . acidophilus preparations have been used in the past.
  • the strains can be used, prior to or concurrently with antibiotic therapy, as a prophylaxis. Such prophylactic administration should occur within 24 hours of the antibiotic therapy.
  • Idiopathic ulcerative colitis also known as inflammatory bowel disease
  • Idiopathic ulcerative colitis also known as inflammatory bowel disease
  • the disease is rather common, and patients suffer recurrent attacks of diarrhea, which can appear on multiple occasions over years of active disease.
  • the only therapies that have proven successful are salicylazosulfapyridine (SAS) and corticosteroids. Many patients relapse despite these treatments.
  • the treatments themselves are associated with a high incidence of side effects.
  • Bacteria of the strains of the invention can be administered, as described above for antibiotic side effects, to treat or prevent ulcerative colitis.
  • Bacteria of the strains of the invention can be employed alone, as described above, or can be admixed with a sub-therapeutic dose of lactulose, a synthetic disaccharide which has been used to treat constipation.
  • the lactulose will be metabolized by the bacteria, enhancing their beneficial effect without producing the side effects which are sometimes associated with therapeutic doses of lactulose.
  • undesirable microorganisms are able to colonize the gastrointestinal tract.
  • these undesirable organisms include Pseudomonas, Enterobacter, Serratia, Klebsiella, Citrobacter and Proteus-Providencia.
  • Fungi can also colonize the gut, especially yeasts such as Candida.
  • the clinical settings in which intestinal colonization with undesirable microorganisms become important include cancer, especially in those patients treated with potent chemotherapy; inherited or acquired immunodeficiency syndromes; patients treated with corticosteroids for a variety of conditions; and recipients of organ transplants such as kidney, bone marrow, heart, and liver.
  • organ transplants such as kidney, bone marrow, heart, and liver.
  • admission to intensive care units often is associated with antibiotic treatment, poor nutritional status, and immunocompromising conditions. This group of high-risk children is also challenged by the problems of colonization with potentially pathogenic bacteria and yeasts.
  • colonization resistance Maintenance of the natural resistance to overgrowth by undesirable microorganisms is known in the recent scientific literature by the term "colonization resistance” (CR).
  • CR colonization resistance
  • Various ploys have been undertaken to either enhance colonization resistance or, alternatively, prevent overgrowth by intestinal microorganisms. Enhancement of CR is achieved by using antibiotics that produce only minimal effects in the composition of the normal intestinal flora, especially by maintaining the normal anaerobic components that seem to be responsible for resisting overgrowth by undesirable microorganisms.
  • the alternative method is prevention of colonization by administering oral antibiotics that essentially kill off any new entrants into the microflora. This method produces a "sterile" microflora, at least for short periods of time.
  • Bacteria of the strains of the invention can be administered to patients, as described above, to provide CR in a benign way, since the bacteria have no intrinsic pathogenicity. Colonization of the intestine by this natural organism could prevent other pathogenic forms from entering the flora, while at the same time maintaining a relatively healthy intestinal environment.
  • Bacteria of the strains of the invention can be administered to patients, as described above, to reduce the amount of cholesterol excreted in the patients' feces.
  • Estrogens are produced largely in the ovaries and, to a lesser extent, in fat and other tissues. The major excretion of estrogens are via the urine.
  • estrogens are conjugated, generally as a glucuruonide or sulfonate. These conjugated estrogens pass through the bile into the intestinal tract, where they are deconjugated by intestinal bacteria and subsequently reabsorbed.
  • Bacteria of the strains of the invention can be administered, as described above, to menstruating women to lower the amount of excreted estrogen; the same deconjugating enzymes involved in estrogen reabsorption are influenced by ingestion of L . acidophilus .
  • the GG strain was deposited in the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 02852, United States of America, on 15 April 1985 and has been given ATCC Accession No. 53103.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dairy Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP86302836A 1985-04-17 1986-04-16 Lactobacillus acidophilus strains of bacteria and compositions thereof Expired - Lifetime EP0199535B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT86302836T ATE71140T1 (de) 1985-04-17 1986-04-16 Lactobacillus-acidophilus-bakterienstaemme und diese enthaltende praeparate.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US724114 1985-04-17
US06/724,114 US4839281A (en) 1985-04-17 1985-04-17 Lactobacillus strains and methods of selection

Publications (4)

Publication Number Publication Date
EP0199535A2 EP0199535A2 (en) 1986-10-29
EP0199535A3 EP0199535A3 (en) 1988-08-03
EP0199535B1 EP0199535B1 (en) 1992-01-02
EP0199535B2 true EP0199535B2 (en) 1995-11-02

Family

ID=24909071

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86302836A Expired - Lifetime EP0199535B2 (en) 1985-04-17 1986-04-16 Lactobacillus acidophilus strains of bacteria and compositions thereof

Country Status (9)

Country Link
US (2) US4839281A (da)
EP (1) EP0199535B2 (da)
JP (1) JPH0648979B2 (da)
AT (1) ATE71140T1 (da)
AU (1) AU597882B2 (da)
DE (1) DE3683184D1 (da)
DK (1) DK171369B1 (da)
FI (1) FI90086C (da)
NO (1) NO169241C (da)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879363B2 (en) 1998-07-07 2011-02-01 Ritter Pharmaceuticals, Inc. Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5804179A (en) * 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US4980164A (en) * 1986-10-02 1990-12-25 Bio Techniques Laboratories, Inc. Strains of lactobacillus for enhancing feed conversion efficiency
US4946791A (en) * 1986-10-02 1990-08-07 Bio Techniques Laboratories, Inc. Novel strain of Lactobacillus acidophilus
CH674150A5 (da) * 1987-10-30 1990-05-15 2 Oi Mo G Med I Im N I Pirogov
DK686187D0 (da) * 1987-12-23 1987-12-23 Hansens Chr Bio Syst Veterinaert praeparat
WO1989011858A1 (en) * 1988-06-09 1989-12-14 Whitecliffe Laboratories Limited Treatment of immunodeficiency
IT1227154B (it) * 1988-08-05 1991-03-19 A Tosi Farmaceutici S R L Nova Composizioni farmaceutiche per uso ginecologico a base di lattobacilli
DK0465677T3 (da) * 1990-01-31 1997-01-20 San Ei Sucrochemical Co Ltd
US5139792A (en) * 1990-07-19 1992-08-18 Bio-Techniques Laboratories, Inc. Method and system for dispensing live bacteria into animal feed and drinking water
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
US5256425A (en) * 1991-08-19 1993-10-26 Bio Techniques Laboratories, Inc. Antibiotic resistant strain of lactobacillus acidophilus
US5179020A (en) * 1991-08-19 1993-01-12 Bio Techniques Laboratories, Inc. Antibiotic resistant strain of lactobacillus acidophilus
DE69227329T3 (de) * 1992-07-06 2003-01-23 Societe Des Produits Nestle S.A., Vevey Milchbakterien
EP0577903B1 (fr) * 1992-07-06 1997-12-17 Societe Des Produits Nestle S.A. Agent antigastrite
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
RU2031586C1 (ru) 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
US6156320A (en) * 1993-02-05 2000-12-05 Harry Parsekian Fermented milk nutraceuticals
AU6244094A (en) * 1993-02-24 1994-09-14 Sherwood L. Gorbach Method of enhancing immune response to oral vaccines
JP2824821B2 (ja) * 1993-11-04 1998-11-18 カルピス株式会社 乳酸菌及び発酵乳製品
US5434765A (en) * 1994-03-10 1995-07-18 Holophane Corporation Luminaire assembly
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
HU220190B (hu) * 1994-05-26 2001-11-28 Bracco S.P.A. Humán eredetű Lactobacillus törzsek, ilyen törzseket tartalmazó gyógyászati készítmények és alkalmazásuk
US5533973A (en) * 1995-01-13 1996-07-09 Abbott Laboratories Alteration of nutritional product during enteral tube feeding
US6036669A (en) 1995-01-13 2000-03-14 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
US6277092B1 (en) 1995-01-13 2001-08-21 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
IT1276783B1 (it) * 1995-06-23 1997-11-03 Bracco Spa Formulazioni farmaceutiche e dietetiche per la profilassi e la cura di affezioni gastrointestinali
FR2740471B1 (fr) * 1995-10-31 1997-12-19 Gervais Danone Co Ferments lactiques, et leur utilisation pour l'obtention de produits hypocholesterolemiants
AT405235B (de) * 1995-11-02 1999-06-25 Helmut Dr Viernstein Probiotisch wirksame formulierung
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
DE69733594T2 (de) * 1996-07-09 2005-11-03 Société des Produits Nestlé S.A. Verfahren zur Sprühtrocknung
IT1284877B1 (it) * 1996-08-09 1998-05-22 Dicofarm Spa Trattamento delle diarree acute del bambino e prevenzione della sensibilizzazione allergica verso alimenti introdotti nella fase
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
ATE217151T1 (de) * 1996-09-06 2002-05-15 Nestle Sa Belüftetes speiseeis mit milchsäurebakterien enthaltende beschichtung
GB9623068D0 (en) * 1996-11-06 1997-01-08 Cultech Limited Microflora
ES2283027T3 (es) * 1996-11-29 2007-10-16 Bio K + International Inc. Fermento lactico que comprende una cepa particular de lactobacilus acidofilus y utilizacion del mismo.
EP1728855A1 (en) * 1996-11-29 2006-12-06 Bio-K Plus International, Inc. Lactic ferment comprising a particular strain of lactobacillus acidopuilus and use thereof
JP4743925B2 (ja) * 1997-02-11 2011-08-10 エンタープライズ アイルランド トレーディング アズ バイオリサーチ アイルランド ラクトバシラス・サリバリウス由来の生体に有益な菌株及びそれより得られた抗菌剤
US6093394A (en) * 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
WO1999002042A2 (fr) 1997-07-05 1999-01-21 Societe Des Produits Nestle S.A. Dessert congele contenant des bacteries lactiques et des fibres fermentescibles
US6080132A (en) * 1998-02-27 2000-06-27 Abbott Laboratories Apparatus for altering characteristics of a fluid
IL140641A (en) * 1998-08-12 2007-07-04 Nestle Sa Incorporation of exogenous lactic bacteria into the oral microflora
EP1159951A1 (en) * 2000-06-02 2001-12-05 Societe Des Produits Nestle S.A. Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases
FR2785809B1 (fr) 1998-11-18 2001-01-12 Gervais Danone Sa Selection et utilisations de souches de bacteries lactiques modulatrices de l'immunite non-specifique
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
IT1312098B1 (it) * 1999-04-23 2002-04-04 Proge Farm Srl Metodo di selezione di ceppi di lattobacilli adesivi con proprieta'terapeutiche e ceppi ottenuti con tale metodo.
US20040197352A1 (en) * 1999-04-30 2004-10-07 Natarajan Ranganathan Methods of improving or augmenting kidney function
US6706287B2 (en) 2001-05-15 2004-03-16 Kibow Biotech Inc. Prebiotic and probiotic compositions and methods for their use in gut-based therapies
US7998470B2 (en) * 1999-04-30 2011-08-16 Kibow Biotech, Inc. Compositions and methods improving renal function
RU2146454C1 (ru) * 1999-05-18 2000-03-20 Анисимова Таисия Ивановна Штамм бактерий lactobacillus acidophilus n.v.ep 317/402 "наринэ" ааа, используемый при приготовлении препаратов, диетических и лечебно-профилактических продуктов для лечения дисбактериоза и его последствий
IL130303A0 (en) 1999-06-03 2000-06-01 M G Novobiotech Ltd A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use
US6251432B1 (en) 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
DE19963104A1 (de) * 1999-12-24 2001-06-28 Ralf Kirkamm Mittel zur Behandlung von Bakterienmangel
EP1296693A4 (en) * 2000-06-19 2005-05-25 Mucoprotec Pty Ltd IMMUNOTHERAPY AND PROBIOTIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL OR VIRAL INFECTIONS ON MUCOSAL SURFACES
IT1320772B1 (it) * 2000-11-02 2003-12-10 Proge Farm Srl Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
US7214370B2 (en) * 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
ATE391509T1 (de) 2000-12-18 2008-04-15 Probio Health Von lactobacillus casei ke01 stamm abgeleitete probiotische verbindungen
FI109602B (fi) 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
SI1485463T1 (sl) * 2002-03-21 2009-02-28 Bifodan As Sevi Lactobacillusa
US7300787B2 (en) * 2002-07-05 2007-11-27 Archer-Daniels-Midland Company Lactobacillus strains and use thereof in fermentation for L-lactic acid production
JP4618970B2 (ja) * 2002-08-02 2011-01-26 マルホ株式会社 肛門圧低下外用剤
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
FI113057B (fi) * 2002-11-04 2004-02-27 Valio Oy Menetelmä hiivojen kasvun estämiseksi
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
ES2633442T3 (es) * 2003-05-22 2017-09-21 Propex Operating Company, Llc Proceso paa la fabricación de artículos poliméricos
AU2004277417B2 (en) 2003-09-30 2010-12-16 Kibow Biotech, Inc. Compositions and methods for augmenting kidney function
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
MY143693A (en) 2004-03-24 2011-06-30 Nestec Sa Shelf stable product wih living micro-organisms
CN1964725A (zh) * 2004-04-20 2007-05-16 芝加哥大学 包含高分子量peg－样化合物的治疗输送系统
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
FR2875406B1 (fr) * 2004-09-21 2007-01-05 Danisco Souche de lactobacillus acidophilus ayant des proprietes analgesiques au niveau du systeme gastro-intestinal
WO2006088923A2 (en) * 2005-02-15 2006-08-24 Gorbach Sherwood L A food containing a probiotic and an isolated beta-glucan and methods of use thereof
US8377430B2 (en) 2005-04-13 2013-02-19 Nestec S.A. Infant formula with probiotics
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
AR053805A1 (es) 2005-05-31 2007-05-23 Iams Company Bifidobacterias probioticas para felinos
JP4938005B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティックであるラクトバシラス
EP2604689B1 (en) 2005-07-26 2015-01-21 Nestec Ltd. Anti-obesity agent and anti-obesity food
SI1931363T1 (sl) 2005-09-28 2016-02-29 Nordisk Rebalance A/S Zdravljenje vnetnih črevesnih bolezni z uporabo probiotičnih bakterij in fermentiranega žita kot efektorjev zdravljenja
PH12012500739A1 (en) 2006-02-15 2013-06-17 Nestec Sa Use of bfidobacterium longum for the prevention and treatment of inflammation
PL1993576T3 (pl) 2006-03-07 2016-04-29 Nestec Sa Mieszanina synbiotyczna
CN103315205A (zh) 2006-03-10 2013-09-25 纽崔西亚公司 不可消化的糖用于在出生后给予婴儿最佳开始的用途
AU2013201783B2 (en) * 2006-10-02 2015-06-04 International N&H Denmark Aps Probiotics for use in reducing the incidence and duration of illness
US7387427B2 (en) * 2006-10-20 2008-06-17 Bristol-Myers Squibb Company Method for blending heat-sensitive material using a conical screw blender with gas injection
US20080095752A1 (en) * 2006-10-20 2008-04-24 Win-Chin Chiang Method for extending the shelf-life of powdered nutritional formulations which contain viable probiotics
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
CN101273736B (zh) * 2007-03-28 2012-08-08 北京弗蒙特生物技术有限公司 一种在常温下保持高活菌数的发酵乳的制备方法
EP1974735A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Reduction of risk of diarrhoea
EP1974743A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
KR20100120169A (ko) 2008-01-24 2010-11-12 네스텍 소시에테아노님 영양 성분을 담고 있는 캡슐 및 이 캡슐로부터 영양액을 전달하는 방법
FI121912B (fi) * 2008-02-05 2011-06-15 Valio Oy Probioottien uusi käyttö
BRPI0909289A2 (pt) 2008-03-14 2015-08-04 Nestec Sa Mistura simbiótica
EP2127661A1 (en) 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2147678A1 (en) 2008-07-21 2010-01-27 Nestec S.A. Probiotics to increase IgA secretion in infants born by caesarean section
CA2750576C (en) 2009-02-02 2019-02-26 Willem Meindert De Vos Novel pilus polypeptides
FI121952B (fi) 2009-05-06 2011-06-30 Oriola Oy Menetelmä pisaroina annosteltavan terveystuotteen valmistamiseksi
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB0914878D0 (en) 2009-08-26 2009-09-30 Plant Bioscience Ltd Competetive exclusion compositions and methods
EP2295535A1 (en) * 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
US20140093614A1 (en) 2009-09-20 2014-04-03 Mead Johnson Nutrition Company Probiotic stabilization
US20110070334A1 (en) 2009-09-20 2011-03-24 Nagendra Rangavajla Probiotic Stabilization
FI20096058A0 (fi) 2009-10-13 2009-10-13 Valio Oy Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
RU2563355C2 (ru) 2009-12-08 2015-09-20 Нестек С.А. Смесь для грудных детей с пробиотиками и компонентами оболочек жировых шариков молока
WO2011141762A1 (en) 2010-05-12 2011-11-17 Compagnie Gervais Danone Synergistic fermentation of lactobacillus rhamnosus and lactobacillus paracasei subsp paracasei
US9474298B2 (en) 2011-10-11 2016-10-25 Mead Johnson Nutrition Company Partially hydrolyzed casein-whey nutritional compositions for reducing the onset of allergies
US20130251829A1 (en) 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
CN104302278B (zh) 2012-03-29 2018-08-21 塞拉拜姆有限责任公司 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
US20130344042A1 (en) 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
EP2900805B1 (en) * 2012-09-25 2022-11-23 Aquilón Cyl S.L. Probiotic and prebiotic compositions
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102617655B1 (ko) 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
EP2953474A4 (en) 2013-02-04 2016-12-28 Seres Therapeutics Inc COMPOSITIONS AND METHODS
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
JP2016531131A (ja) 2013-08-22 2016-10-06 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオーＮｅｄｅｒｌａｎｄｓｅ Ｏｒｇａｎｉｓａｔｉｅ ｖｏｏｒ ｔｏｅｇｅｐａｓｔ−ｎａｔｕｕｒｗｅｔｅｎｓｃｈａｐｐｅｌｉｊｋ ｏｎｄｅｒｚｏｅｋ ＴＮＯ ヒト又は動物の微生物叢由来の有利な微生物のｉｎ ｖｉｔｒｏの濃縮によるプロバイオティクスの生成
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US20150305359A1 (en) 2014-04-24 2015-10-29 Mead Johnson Nutrition Company Nutritional compositions directed to subjects having cow's milk protein allergies
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US10525016B2 (en) 2015-06-03 2020-01-07 Mead Johnson Nutrition Company Nutritional compositions containing an elevated level of inositol and uses thereof
AU2016349364A1 (en) 2015-11-03 2018-05-24 The Brigham And Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
US9730969B2 (en) 2015-11-06 2017-08-15 Mead Johnson Nutrition Company Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
EP3373748A1 (en) 2015-11-09 2018-09-19 MJN U.S. Holdings LLC Nutritional compositions comprising a casein hydrolysate, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
US20180161292A1 (en) 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions containing butyrate and uses thereof
US20180160714A1 (en) 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions containing butyrate and uses thereof
ES2965306T3 (es) 2016-12-16 2024-04-12 Gervais Danone Sa Composición probiótica que comprende cepas de Lactobacillus rhamnosus y Lactobacillus paracasei
US20180168215A1 (en) 2016-12-21 2018-06-21 Mead Johnson Nutrition Company Nutritional compositions containing inositol and uses thereof
US20180332881A1 (en) 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Preterm infant formula containing butyrate and uses thereof
DE102017113263A1 (de) 2017-06-16 2018-12-20 Lactopia GmbH Pharmazeutische Zusammensetzung enthaltend Bakterienstämme aus der Familie der Lactobacillaceae und Molke
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
RU2020117775A (ru) 2017-10-30 2021-12-01 Серес Терапеутикс, Инк. Композиции и способы для лечения устойчивости к антибиотикам
US20190208807A1 (en) 2018-01-05 2019-07-11 Mead Johnson Nutrition Company Nutritional compositions containing milk-derived peptides and uses thereof
CN113194971A (zh) 2018-09-10 2021-07-30 拉克托拜欧有限公司 用于减少病原微生物转移的方法
EP3897568A1 (en) 2018-12-21 2021-10-27 Lactobio A/S Topical composition comprising viable microorganisms
BR112021013190A2 (pt) 2019-01-04 2021-09-28 Lactobio A/S Cepa bacteriana isolada, composição e uso de composição
WO2020234382A1 (en) 2019-05-20 2020-11-26 Lactobio Aps Composition for treatment, alleviation or prophylaxis of acne
MY199150A (en) 2019-06-05 2023-10-18 Morinaga Milk Industry Co Ltd Nutritional composition
CN114245748A (zh) 2019-06-13 2022-03-25 莱托生物股份有限公司 包含活微生物的凝胶组合物
ES2983662T3 (es) 2019-07-23 2024-10-24 Frieslandcampina Nederland Bv Composición nutricional que comprende grasa láctea e inmunoglobulina
WO2024245585A1 (en) 2023-05-30 2024-12-05 L'oréal Topical formulation comprising deliquescent substance
WO2025036982A1 (en) 2023-08-16 2025-02-20 L'oréal New container, method and delivery system stabilizing topical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL294835A (da) 1962-07-19 1900-01-01
LU44002A1 (da) 1962-07-19 1963-09-03
DE1617755A1 (de) * 1966-10-21 1972-02-17 Rehm Eberhard Verfahren zur Herstellung eines durch selektive Zuechtung von Laktobakterien erhaltenen Praeparates
GB1167196A (en) * 1966-12-12 1969-10-15 Yakult Honsha Kk Lactic Acid Bacteria.
FI59925C (fi) * 1980-01-11 1981-11-10 Esko Viljo Nurmi Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae
IT1141095B (it) * 1980-11-27 1986-10-01 Ravizza Spa Processo di risoluzione della sulpiride racema
US4525351A (en) * 1983-01-11 1985-06-25 Chr. Hansen's Laboratory, Inc. Liquid adherent disinfectant compositions for topical application and method of preparation
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879363B2 (en) 1998-07-07 2011-02-01 Ritter Pharmaceuticals, Inc. Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9579340B2 (en) 2009-02-24 2017-02-28 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9592248B2 (en) 2009-02-24 2017-03-14 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9775860B2 (en) 2009-02-24 2017-10-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use

Also Published As

Publication number Publication date
JPS61280433A (ja) 1986-12-11
AU5611286A (en) 1987-10-22
AU597882B2 (en) 1990-06-14
NO861483L (no) 1986-10-20
JPH0648979B2 (ja) 1994-06-29
FI860194L (fi) 1986-10-18
DE3683184D1 (de) 1992-02-13
EP0199535B1 (en) 1992-01-02
FI90086B (fi) 1993-09-15
FI90086C (fi) 1993-12-27
DK171369B1 (da) 1996-09-30
DK170186D0 (da) 1986-04-15
FI860194A0 (fi) 1986-01-16
NO169241B (no) 1992-02-17
EP0199535A3 (en) 1988-08-03
ATE71140T1 (de) 1992-01-15
NO169241C (no) 1992-05-27
DK170186A (da) 1986-10-18
EP0199535A2 (en) 1986-10-29
US4839281A (en) 1989-06-13
US5032399A (en) 1991-07-16

Similar Documents

Publication Publication Date Title
EP0199535B2 (en) Lactobacillus acidophilus strains of bacteria and compositions thereof
AU673525B2 (en) Lactic acid bacterium
CN108004189B (zh) 一种复合益生乳酸菌粉剂及其制备方法与应用
JP3186202B2 (ja) 親生物
US7150986B2 (en) Lactic acid bacteria-containing probiotics products
CN1297653C (zh) 包含戊糖乳杆菌菌株的组合物及其用途
JP4072646B2 (ja) 上皮接着性乳酸桿菌
USRE39585E1 (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
ES2231908T3 (es) Cepas novedosas de lactobacilos utiles en el tratamiento de trastornos del aparato digestivo.
TWI304736B (da)
EP0554418A1 (en) Intestine colonizing lactobacilli
JPH09241173A (ja) 乳酸菌を有効成分とする抗胃炎剤、抗潰瘍剤および醗酵食品
GB2338244A (en) A beneficial microbe composition, new protective materials for the microbes, the method to prepare the same and uses thereof
CN113832077A (zh) 鼠李糖乳杆菌及其应用
MXPA97001816A (en) Bacterials and pharmaceutical composition containing such strains and using the same to prevent and treat diseases associated with metabolism altered biliary deactives or caused by my
FI95193C (fi) Uusi Lactobacillus acidophilus-kanta ja sen käyttö elintarvikkeiden, erityisesti meijerituotteiden valmistamiseen
KR100523661B1 (ko) 결장 내에서 프로피온산 및/또는 프로피오네이트를생성하기 위한 프로피온 박테리아의 용도
US20220233618A1 (en) Composition containing a yeast for preventing simple and/or recurring cystitis
Dash Review of scientific evidence for efficacy of Lactobacillus acidophilus DDS-1 as a probiotic strain
EP1212066A1 (en) Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
WO1994026114A1 (en) Method of stimulating and modulating the immune system of animals with microbial compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19890130

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GOLDIN, BARRY R.

Owner name: GORBACH, SHERWOOD L.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GOLDIN, BARRY R.

Inventor name: GORBACH, SHERWOOD L.

17Q First examination report despatched

Effective date: 19901108

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19920102

REF Corresponds to:

Ref document number: 71140

Country of ref document: AT

Date of ref document: 19920115

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3683184

Country of ref document: DE

Date of ref document: 19920213

ITF It: translation for a ep patent filed
ET Fr: translation filed
PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: UNILEVER N.V.

Effective date: 19921002

NLR1 Nl: opposition has been filed with the epo

Opponent name: UNILEVER N.V.

ITTA It: last paid annual fee
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 86302836.1

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 19951102

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REG Reference to a national code

Ref country code: CH

Ref legal event code: AEN

Free format text: MAINTIEN DU BREVET DONT L'ETENDUE A ETE MODIFIEE

ITF It: translation for a ep patent filed
NLR2 Nl: decision of opposition
ET3 Fr: translation filed ** decision concerning opposition
NLR3 Nl: receipt of modified translations in the netherlands language after an opposition procedure
REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: SHERWOOD L. GORBACH;BARRY R. GOLDIN TRANSFER- GORB

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

NLS Nl: assignments of ep-patents

Owner name: GORBACH-GOLDIN CORPORATION

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

BECA Be: change of holder's address

Free format text: 19990112 *GORBACH-GOLDIN CORP.:31 PERRY LANE, WESTON MASSACHUSETTS 02193

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050330

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050406

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050414

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050415

Year of fee payment: 20

Ref country code: NL

Payment date: 20050415

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20050418

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20050420

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20050425

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050427

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20060415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20060416

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20060416

EUG Se: european patent has lapsed
BE20 Be: patent expired

Owner name: *GORBACH-GOLDIN CORP.

Effective date: 20060416